Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsFRA:6XY -3.73%62 EV-to-EBITDA is 12.46 as of Aug. 20, 2026, which is 1788% above its 10-year median of 0.66. GuruFocus rates FRA:6XY with a GF Score™ of 62/100 and a GF Value™ of €0.76 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 402 Biotechnology companies, HBM Holdings ranks worse than 51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, HBM Holdings's enterprise value is €1,056.3 Mil.
HBM Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €84.8 Mil. Therefore, HBM Holdings's EV-to-EBITDA for today is 12.46.
The historical rank and industry rank for HBM Holdings's EV-to-EBITDA or its related term are showing as below:
FRA:6XY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.23 Med: 0.66 Max: 157.69
Current: 12.43
During the past 8 years, the highest EV-to-EBITDA of HBM Holdings was 157.69. The lowest was -16.23. And the median was 0.66.
FRA:6XY's EV-to-EBITDA is ranked worse than 51% of 402
companies
in the Biotechnology industry
Industry Median: 14.41
vs FRA:6XY: 12.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HBM Holdings's PE Ratio (TTM) for today is calculated as:
HBM Holdings's share price for today is €1.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.104.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for HBM Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6XY vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, HBM Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HBM Holdings's EV-to-EBITDA falls into.
HBM Holdings's current Enterprise Value is €1,056.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €84.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (FRA:6XY) has a EV-to-EBITDA of 12.46 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on HBM Holdings. This is 1788% above median its historical median of 0.66. According to the industry distribution chart, HBM Holdings ranks #205 out of 402 companies in the Biotechnology industry, placing it in the top 51%.
Is HBM Holdings' EV-to-EBITDA too high?
HBM Holdings' current EV-to-EBITDA of 12.46 is 1788% above median its 10-year median of 0.66. The Biotechnology industry median EV-to-EBITDA is 14.41. HBM Holdings' value of 12.46 is 13.5% below this industry median. Based on the distribution chart, HBM Holdings ranks #205 out of 402 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HBM Holdings has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #205 out of 402 companies for EV-to-EBITDA. This places HBM Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 14.41. HBM Holdings' value of 12.46 is 13.5% below this benchmark. While the company's 10-year median is 0.66 vs. the industry median of 14.41, HBM Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.41, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current EV-to-EBITDA of 12.46 is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on HBM Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 14.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current EV-to-EBITDA is 12.46, which is 1788% above median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (FRA:6XY) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.76, compared to a current price of €1.55 — trading 103.9% above its estimated fair value. The current EV-to-EBITDA is 12.46, which is 1788% above median its 10-year median of 0.66 and 13.5% below the Biotechnology industry median of 14.41. HBM Holdings' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For HBM Holdings (FRA:6XY), the current EV-to-EBITDA is 12.46 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (FRA:6XY) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of €1.55 is trading 103.9% above its estimated GF Value™ of €0.76.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for FRA:6XY:
EV-to-EBITDA: 12.46 (1788% above median its 10-year median of 0.66)
GF Value™: €0.76 vs. price of €1.55 (103.9% above fair value)
Industry Position: 13.5% below the Biotechnology median (#205 of 402)
No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
62GF Score
Get the complete analysis for FRA:6XY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XY has been successfully added to your 
